Literature DB >> 21831840

Wild-type p53 controls cell motility and invasion by dual regulation of MET expression.

Chang-Il Hwang1, Andres Matoso, David C Corney, Andrea Flesken-Nikitin, Stefanie Körner, Wei Wang, Carla Boccaccio, Snorri S Thorgeirsson, Paolo M Comoglio, Heiko Hermeking, Alexander Yu Nikitin.   

Abstract

Recent observations suggest that p53 mutations are responsible not only for growth of primary tumors but also for their dissemination. However, mechanisms involved in p53-mediated control of cell motility and invasion remain poorly understood. By using the primary ovarian surface epithelium cell culture, we show that conditional inactivation of p53 or expression of its mutant forms results in overexpression of MET receptor tyrosine kinase, a crucial regulator of invasive growth. At the same time, cells acquire increased MET-dependent motility and invasion. Wild-type p53 negatively regulates MET expression by two mechanisms: (i) transactivation of MET-targeting miR-34, and (ii) inhibition of SP1 binding to MET promoter. Both mechanisms are not functional in p53 absence, but mutant p53 proteins retain partial MET promoter suppression. Accordingly, MET overexpression, cell motility, and invasion are particularly high in p53-null cells. These results identify MET as a critical effector of p53 and suggest that inhibition of MET may be an effective antimetastatic approach to treat cancers with p53 mutations. These results also show that the extent of advanced cancer traits, such as invasion, may be determined by alterations in individual components of p53/MET regulatory network.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21831840      PMCID: PMC3161601          DOI: 10.1073/pnas.1017536108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  49 in total

1.  CD44 is required for two consecutive steps in HGF/c-Met signaling.

Authors:  Véronique Orian-Rousseau; Linfeng Chen; Jonathan P Sleeman; Peter Herrlich; Helmut Ponta
Journal:  Genes Dev       Date:  2002-12-01       Impact factor: 11.361

2.  Sp1 and Sp3 transcription factors synergistically regulate HGF receptor gene expression in kidney.

Authors:  Xianghong Zhang; Yingjian Li; Chunsun Dai; Junwei Yang; Peter Mundel; Youhua Liu
Journal:  Am J Physiol Renal Physiol       Date:  2003-01

3.  Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer.

Authors:  J M Piek; P J van Diest; R P Zweemer; J W Jansen; R J Poort-Keesom; F H Menko; J J Gille; A P Jongsma; G Pals; P Kenemans; R H Verheijen
Journal:  J Pathol       Date:  2001-11       Impact factor: 7.996

4.  p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.

Authors:  T Hashimoto; Y Tokuchi; M Hayashi; Y Kobayashi; K Nishida; S Hayashi; Y Ishikawa; S Tsuchiya; K Nakagawa; J Hayashi; E Tsuchiya
Journal:  Cancer Res       Date:  1999-11-01       Impact factor: 12.701

5.  Sp1 plays a critical role in the transcriptional activation of the human cyclin-dependent kinase inhibitor p21(WAF1/Cip1) gene by the p53 tumor suppressor protein.

Authors:  G Koutsodontis; I Tentes; P Papakosta; A Moustakas; D Kardassis
Journal:  J Biol Chem       Date:  2001-05-30       Impact factor: 5.157

6.  Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium.

Authors:  Andrea Flesken-Nikitin; Kyung-Chul Choi; Jessica P Eng; Elena N Shmidt; Alexander Yu Nikitin
Journal:  Cancer Res       Date:  2003-07-01       Impact factor: 12.701

7.  p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug.

Authors:  Shu-Ping Wang; Wen-Lung Wang; Yih-Leong Chang; Chen-Tu Wu; Yu-Chih Chao; Shih-Han Kao; Ang Yuan; Chung-Wu Lin; Shuenn-Chen Yang; Wing-Kai Chan; Ker-Chau Li; Tse-Ming Hong; Pan-Chyr Yang
Journal:  Nat Cell Biol       Date:  2009-05-17       Impact factor: 28.824

8.  Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene.

Authors:  Selma Pennacchietti; Paolo Michieli; Maria Galluzzo; Massimiliano Mazzone; Silvia Giordano; Paolo M Comoglio
Journal:  Cancer Cell       Date:  2003-04       Impact factor: 31.743

Review 9.  Why did p53 gene therapy fail in ovarian cancer?

Authors:  Alain G Zeimet; Christian Marth
Journal:  Lancet Oncol       Date:  2003-07       Impact factor: 41.316

10.  Spectrum of p53 tumor suppressor gene mutations and breast cancer survival.

Authors:  Hong Lai; Fangchao Ma; Edward Trapido; Lou Meng; Shenghan Lai
Journal:  Breast Cancer Res Treat       Date:  2004-01       Impact factor: 4.872

View more
  65 in total

1.  MET-dependent cancer invasion may be preprogrammed by early alterations of p53-regulated feedforward loop and triggered by stromal cell-derived HGF.

Authors:  Chang-Il Hwang; Jinhyang Choi; Zongxiang Zhou; Andrea Flesken-Nikitin; Alexander Tarakhovsky; Alexander Yu Nikitin
Journal:  Cell Cycle       Date:  2011-11-15       Impact factor: 4.534

2.  MYH9 binds to lncRNA gene PTCSC2 and regulates FOXE1 in the 9q22 thyroid cancer risk locus.

Authors:  Yanqiang Wang; Huiling He; Wei Li; John Phay; Rulong Shen; Lianbo Yu; Baris Hancioglu; Albert de la Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-03       Impact factor: 11.205

3.  Mutant P53 induces MELK expression by release of wild-type P53-dependent suppression of FOXM1.

Authors:  Lakshmi Reddy Bollu; Jonathan Shepherd; Dekuang Zhao; Yanxia Ma; William Tahaney; Corey Speers; Abhijit Mazumdar; Gordon B Mills; Powel H Brown
Journal:  NPJ Breast Cancer       Date:  2020-01-03

4.  Mutant p53 expression in fallopian tube epithelium drives cell migration.

Authors:  Suzanne M Quartuccio; Subbulakshmi Karthikeyan; Sharon L Eddie; Daniel D Lantvit; Eoghainín Ó hAinmhire; Dimple A Modi; Jian-Jun Wei; Joanna E Burdette
Journal:  Int J Cancer       Date:  2015-04-11       Impact factor: 7.396

5.  miR-34 cooperates with p53 in suppression of prostate cancer by joint regulation of stem cell compartment.

Authors:  Chieh-Yang Cheng; Chang-Il Hwang; David C Corney; Andrea Flesken-Nikitin; Longchang Jiang; Gülfem Meryem Öner; Robert J Munroe; John C Schimenti; Heiko Hermeking; Alexander Yu Nikitin
Journal:  Cell Rep       Date:  2014-03-13       Impact factor: 9.423

Review 6.  MicroRNA and MET in lung cancer.

Authors:  Matteo Brighenti
Journal:  Ann Transl Med       Date:  2015-04

7.  Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence.

Authors:  Valentina Martin; Simona Corso; Paolo M Comoglio; Silvia Giordano
Journal:  Mol Oncol       Date:  2014-06-24       Impact factor: 6.603

8.  Obligate progression precedes lung adenocarcinoma dissemination.

Authors:  Deborah R Caswell; Chen-Hua Chuang; Dian Yang; Shin-Heng Chiou; Shashank Cheemalavagu; Caroline Kim-Kiselak; Andrew Connolly; Monte M Winslow
Journal:  Cancer Discov       Date:  2014-04-16       Impact factor: 39.397

Review 9.  The biological functions of miRNAs: lessons from in vivo studies.

Authors:  Joana A Vidigal; Andrea Ventura
Journal:  Trends Cell Biol       Date:  2014-12-04       Impact factor: 20.808

10.  Human papillomavirus oncoprotein E6 upregulates c-Met through p53 downregulation.

Authors:  Guoqing Qian; Dongsheng Wang; Kelly R Magliocca; Zhongliang Hu; Sreenivas Nannapaneni; Sungjin Kim; Zhengjia Chen; Shi-Yong Sun; Dong M Shin; Nabil F Saba; Zhuo G Chen
Journal:  Eur J Cancer       Date:  2016-07-22       Impact factor: 9.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.